From September 6th to 9th, the 41st China Pharmaceutical Industry Information Annual Conference was held in Chengdu, where the highly anticipated rankings for the Top 100 Chinese Pharmaceutical Industries, along with a series of special rankings, were ceremoniously released by the Ministry of Industry and Information Technology. Hansoh Pharma's chief subsidiary, Jiangsu Hansoh Pharma, has been ranked among the Top 100 Chinese Pharmaceutical Industries. Boasting outstanding innovative achievements and exceptional comprehensive competitiveness, it ranked among the top three in the "Best Industrial Enterprise for Pharmaceutical R&D Product Line in China" for eight consecutive years.
The "Best Industrial Enterprise for Pharmaceutical R&D Product Line in China” is one of the most authoritative and representative industry ranking events in China. The list is meticulously curated by a professional panel based on objective data and research analysis. Amid significant changes in the pharmaceutical industry in China and worldwide, the companies on the list have shown remarkable resilience in their innovative development.
In the first half of 2024, Hansoh Pharma's R&D expenditure reached approximately 1.196 billion RMB, representing a record high year-on-year increase of around 28.7%. Currently, the company has established R&D centers in Maryland in the United States as well as in Shanghai, Changzhou, and Lianyungang in China, which altogether are supported by over 1700 professional research staff. To further establish a hub for cutting-edge scientific innovation and a leading center for technology, Hansoh Pharma began the construction of its global R&D headquarter in Shanghai in March 2024, spanning over 90,000 square meters.
Driven by both independent research and external collaborations, Hansoh Pharma is dedicated to addressing unmet clinical needs. By leveraging advanced international technology platforms such as ADCs, monoclonal antibodies, bispecific antibodies, siRNA, and fusion proteins, the company is strengthening its presence in oncology while expanding into fields such as anti-infection, central nervous system disorders, metabolic diseases, and autoimmune conditions. Currently, Hansoh Pharma has over 30 innovative drugs in more than 50 clinical trials.
"Innovation + internationalization" has become the new drivers of sustainable growth for Hansoh Pharma. While maintaining a strong focus on independent research and development, the company has established 11 collaborative projects and successfully licensed global rights for two of its self-developed ADC products to leading international pharmaceutical companies. This strategy is designed to accelerate the translation of research outcomes and benefit patients both in China and worldwide.
